



SARS NC (3851): sc-58192

BACKGROUND

Severe acute respiratory syndrome (SARS), a recently emergent respiratory disease characterized by atypical pneumonia with short two to seven day incubation periods, is caused by a coronavirus. Sharing little homology with previously known coronaviruses, the SARS virus seems to be the first coronavirus that consistently causes severe disease in humans. Coronaviruses maintain enveloped structures, utilizing positive-sense single-stranded RNA to replicate in the cytoplasm of host cells. Coronavirus RNA synthesis retains a very high rate of RNA-RNA recombination, allowing extensive evolution of unique species such as SARS. Most viral particles show the appearance of spike-like surface projections, giving rise to the virus name, which is Latin for crown. These transmembrane spikes protrude 20 nanometers from the surface. The nucleoprotein of the SARS virus, also known as SARS nucleocapsid or SARS NC, is the basic architecture of the virus, comprised of a core of nucleic acid captured in a protein coat.

REFERENCES

1. He, L., Ding, Y., Zhang, Q., Che, X., He, Y., Shen, H., Wang, H., Li, Z., Zhao, L., Geng, J., Deng, Y., Yang, L., Li, J., Cai, J., Qiu, L., Wen, K., Xu, X. and Jiang, S. 2006. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2⁺ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. *J. Pathol.* 210: 288-297.
2. Cheng, C., Wong, W.M. and Tsang, K.W. 2006. Perception of benefits and costs during SARS outbreak: an 18-month prospective study. *J. Consult. Clin. Psychol.* 74: 870-879.
3. Ren, W., Li, W., Yu, M., Hao, P., Zhang, Y., Zhou, P., Zhang, S., Zhao, G., Zhong, Y., Wang, S., Wang, L.F. and Shi, Z. 2006. Full-length genome sequences of two SARS-like coronaviruses in horseshoe bats and genetic variation analysis. *J. Gen. Virol.* 87: 3355-3359.
4. Shao, H., Lan, D., Duan, Z., Liu, Z., Min, J., Zhang, L., Huang, J., Su, J., Chen, S. and Xu, A. 2006. Upregulation of mitochondrial gene expression in PBMC from convalescent SARS patients. *J. Clin. Immunol.* 26: 546-554.
5. Liu, M., Gu, C., Wu, J. and Zhu, Y. 2006. Amino acids 1 to 422 of the spike protein of SARS associated coronavirus are required for induction of cyclooxygenase-2. *Virus Genes* 33: 309-317.
6. Kuba, K., Imai, Y., Rao, S., Jiang, C. and Penninger, J.M. 2006. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. *J. Mol. Med.* 84: 814-820.
7. Al-Hajjar, S. 2006. SARS: challenge of the new century. *Ann. Saudi Med.* 23: 116-117.
8. Smith, R.D. 2006. Responding to global infectious disease outbreaks: lessons from role of risk perception, communication and management. *Soc. Sci. Med.* 63: 3113-3123.
9. Stockman, L.J., Bellamy, R. and Garner, P. 2006. SARS: systematic review of treatment effects. *PLoS Med.* 3: e343.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

SOURCE

SARS NC (3851) is a mouse monoclonal antibody raised against SARS virus.

PRODUCT

Each vial contains 100 µg IgG_{2b} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

SARS NC (3851) is recommended for detection of nucleocapsid (NC) of SARS virus origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Molecular Weight of SARS NC: 46 kDa.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.